Meta sues developers of 'nudify' apps for running ads on its platforms
June 12 (UPI) -- Meta is suing a company for an app that allows people to create AI-generated nude or sexually explicit images without their consent, the social media company said Thursday.
Meta filed a lawsuit in Hong Kong to prevent, Joy Timeline HK limited, the company behind CrushAI Apps, from advertising its apps on Meta's platforms.
The company initially ran ads on Facebook and Instagram to promote CrushAi.
"This follows multiple attempts by Joy Timeline HK Limited to circumvent Meta's ad review process and continue placing these ads, after they were repeatedly removed for breaking our rules," Meta said.
"This legal action underscores both the seriousness with which we take this abuse and our commitment to doing all we can to protect our community from it," Meta said. "We'll continue to take the necessary steps -- which could include legal action -- against those who abuse our platforms like this."
Sen. Dick Durbin, D-IIl., sent a letter in February to warn Mark Zuckerberg about allowing his companies to run ads by Joy timeline that break Meta's standards.
To tackle more online harm, Meta said it is increasing its "enforcement methods."
"We've developed new technology specifically designed to identify these types of ads," Meta said. "Even when the ads themselves don't include nudity and use matching technology to help us find and remove copycat ads more quickly."
Meta said it's working with "experts and specialist teams" to upgrade their system in picking up these ads.
"Since the start of the year, our expert teams have run in-depth investigations to expose and disrupt four separate networks of accounts that were attempting to run ads promoting these services," said Meta.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
I missed Nvidia – could this be the next big US growth stock?
Let's be honest — most of us missed the boat on Nvidia (NASDAQ: NVDA). And by the time we realised just how vital graphics processing units (GPUs) would become to artificial intelligence (AI), the share price had already soared into the stratosphere. Over the past five years, the stock has climbed almost 1,600%. In the last six months alone, it's up almost 50%, adding over $1.5trn to its market value. It's now the most valuable company in the world, overtaking Microsoft and Apple in June. I have exposure to the stock through several ETFs and investment trusts, so I didn't entirely miss out on the action. But I certainly made nowhere near the gains I would have had I bought individual shares. Which makes me wonder, how did Nvidia get here, and what stock could be next? Crunching the numbers The numbers behind the hype are jaw-droppingly impressive. For the fiscal year ending January 2025, revenue reached $130bn, a staggering increase from $27bn just two years ago. Net income exploded from $4.3bn in 2022 to more than $70bn this year. And its margins are enormous — a return on equity of 115% and gross margins consistently above 70%. Yet despite the parabolic growth, I don't think it's entirely overvalued yet. In fact, I still think it's worth considering as a long-term investment. It's a world-class company with room to expand further and the global AI arms race is just getting started – with Nvidia at its core. Realistically, though, the biggest gains have already been made. Buying now means betting on continued dominance that may already be priced in, which is a risk. The stock trades at a price-to-earnings (P/E) ratio of 45 – not outrageous considering its growth, but not cheap either. So where should investors look if they want to catch the next killer growth stock before it becomes a trillion-dollar giant? Could SymphonyAI be next? One company on my radar is SymphonyAI, a private US firm reportedly preparing for a Nasdaq IPO later this year. It's not yet listed, but when it does go public, I'll be watching closely. Founded by billionaire Romesh Wadhwani, it specialises in applying AI to specific industry verticals – retail, finance, manufacturing, and healthcare. It doesn't build chips like Nvidia, but it builds the enterprise software that helps businesses harness AI to improve decision-making and productivity. Unlike many AI startups, SymphonyAI already has real revenues and customers. Its retail division serves over 1,200 brands, while its industrial arm works with giants like Nestlé and ArcelorMittal. While financials are still private, it reportedly generates hundreds of millions in annual revenue and is growing fast. If the IPO goes ahead this autumn, it could be one of the most closely watched tech listings of the year. Long-term mindset Nvidia's success was powered by timing, technology, and a growing reliance on data. It may still reward shareholders but the days of 10x returns are likely behind us. SymphonyAI might never reach Nvidia's heights but it could offer early-stage exposure to enterprise AI – the next leg of this growth story. If the valuation is right, it could turn out to be a once-in-a-decade opportunity. The post I missed Nvidia – could this be the next big US growth stock? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Mark Hartley has no position in any of the shares mentioned. The Motley Fool UK has recommended Apple, Microsoft, and Nvidia. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
Tempus AI, Inc. TEM is scheduled to report second-quarter 2025 results on Aug. 8. In the last reported quarter, the company's adjusted loss of 24 cents was narrower than the Zacks Consensus Estimate of a loss of 27 cents per share. Tempus AI, which went public in June 2024, exceeded estimates in two of the trailing four quarters and missed in two, the average negative earnings surprise being 2.07%. The Zacks Consensus Estimate for revenues is currently pegged at $299.3 million for the second quarter, implying an 80.4% improvement over the year-ago period. The Zacks Consensus Estimate for the second-quarter bottom line has narrowed by 4 cents to a loss of 23 cents per share over the past 90 days. TEM's Earnings Estimate Revision Trend Image Source: Zacks Investment Research Throughout the second quarter of 2025, Tempus AI had an impressive run on the bourses with a 34.5% gain. Despite macroeconomic challenges, including escalating trade tensions that broadly impacted the healthcare technology sector, the company witnessed strong momentum, primarily driven by a series of strategic acquisitions and partnerships in the field of AI-driven precision medicine. During this period, the company not only surpassed the 9.3% gain posted by the broader industry but also significantly outperformed the 3.4% decline of the Medical sector. The S&P 500 benchmark index gained 10.7% during this period. The company has also outperformed other players in the health infotech field, like 10x Genomics TXG and SOPHiA GENETICS SOPH. While TXG gained 33.5%, SOPH declined 2.3% during the said period. Q2 Price Comparison Image Source: Zacks Investment Research Let's see how things have shaped up for TEM shares prior to this announcement: Key Factors to Note Prior to Tempus AI's Q2 Earnings Tempus AI recently announced a three-year, $200 million foundational model partnership with AstraZeneca AZN and Pathos, which is expected to have contributed to its second-quarter performance. This non-exclusive data licensing agreement aims to develop the world's largest foundation model in oncology using over 300 petabytes of Tempus' multimodal data. With the first version of the model expected in 9-12 months, the deal is already transforming Tempus AI's data monetization trajectory. Management confirmed that revenues from this deal will be recognized ratably over the three-year term, starting in the second quarter. Tempus AI's hereditary testing segment, which contributed meaningfully to first-quarter growth, is expected to have maintained the trend this time too. When Tempus acquired Ambry Genetics, it guided mid-to-high teens growth, but the segment exceeded expectations with a 23% unit increase. While management has been cautious about projecting ongoing acceleration, they have also expressed confidence in the long-term potential for broader hereditary screening applications, ranging from cancer to cardiovascular and neurological risk. Tempus continued to expand its diagnostics portfolio with the recent FDA clearance of ECG-Low EF, its second AI-powered ECG tool for detecting low ejection fraction, further strengthening its position in cardiology and extending its reach beyond oncology. Meanwhile, the company launched xM for TRM, a liquid biopsy assay for monitoring immunotherapy response, which showed promising early data at ASCO 2025. These likely contributed to the second-quarter top line too. Tempus AI is advancing its digital health strategy by integrating Tempus One, its GenAI clinical assistant, into EHR systems, enabling physicians to query data, access guidelines and streamline workflows. The launch of Agent Builder for custom GenAI tools further deepens its role in clinical settings. Tempus One too is expected to have witnessed strong customer adoption during the second quarter. However, despite strong top-line growth and product momentum, Tempus AI in 2025 is facing a few near-term challenges. The company remains unprofitable, with an adjusted EBITDA loss of $16.2 million in the first quarter. Though the loss narrowed year over year, it raised questions about the timeline to profitability amid ongoing R&D investments. Additionally, while the AstraZeneca-Pathos foundation model deal is significant, its revenues will be recognized ratably over three years, limiting short-term financial impact. Further, investments tied to these updates, including product development, regulatory efforts, and marketing, are likely to have pushed operating expenses higher in the second quarter, putting some pressure on short-term profitability. Broader macroeconomic factors, like tariffs, hospital budget constraints and biotech funding trends, could also affect adoption rates. Expensive Valuation TEM's stock is currently overvalued compared to its industry, as shown in the chart below. TEM is currently trading at a forward 12-month price-to-sales (P/S) ratio of 6.86, a premium to the broader industry's average of 5.80X. It also trades higher than other industry players like 10x Genomics (2.70X) and SOPHiA GENETICS (2.40X). However, the stock is trading below its one-year median of 8.00X, suggesting that it has moderated somewhat from its historical highs. Image Source: Zacks Investment Research Our Take With the AI market projected to grow exponentially in the coming years, Tempus AI is well-positioned to capitalize on expanding opportunities. With a strong financial outlook and efforts to improve healthcare outcomes, TEM presents a unique opportunity for investors seeking high returns from the AI and healthcare sectors. Yet, despite the company's several recent upsides, its premium valuation and lack of near-term profitability are limiting this Zacks Rank #3 (Hold) stock's near-term gains. While current shareholders should hold their positions, new investors should wait for the stock to retract some of its recent gains, providing a better entry point. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report 10x Genomics (TXG) : Free Stock Analysis Report SOPHiA GENETICS SA (SOPH) : Free Stock Analysis Report Tempus AI, Inc. (TEM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
2 hours ago
- Business Insider
Meta Is Now Targeting Startups that Specialize in AI Videos
Social media firm Meta Platforms (META) is continuing its aggressive push into artificial intelligence by targeting startups that specialize in creating and editing AI-generated videos. According to The Information, Meta recently held talks with Pika, a startup that builds realistic video-generation tools, about a possible acquisition or licensing deal. Discussions with another startup, Higgsfield, have ended, while similar talks with Runway earlier this year also failed to progress. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Nevertheless, advanced video AI could play a key role in CEO Mark Zuckerberg's vision for 'personal superintelligence,' which focuses on entertainment, culture, and personal relationships. It would also strengthen Meta's push into smart glasses and virtual reality, areas where it has invested tens of billions of dollars. Furthermore, Meta recently added AI-powered video-editing tools to its Meta AI assistant and Instagram's Edits app, with Zuckerberg telling analysts that these features are 'seeing early progress.' As a result, a partnership with Pika or similar startups could help Meta keep up with competitors. It is worth noting that this strategy comes as Meta overhauls its AI operations after earlier setbacks. Indeed, the company recently appointed Scale AI CEO Alexandr Wang as chief AI officer and invested over $14 billion in Scale. Meta also brought in former GitHub CEO Nat Friedman and Safe Superintelligence co-founder Daniel Gross, who now co-lead Meta Superintelligence Labs, its new AI division. In addition, Meta recently acquired voice AI startup PlayAI and poached top researchers from rivals like OpenAI, Anthropic, and Google (GOOGL) in order to accelerate its progress. Is Meta a Buy, Sell, or Hold? Turning to Wall Street, analysts have a Strong Buy consensus rating on META stock based on 43 Buys, three Holds, and zero Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average META price target of $850.98 per share implies 22.4% upside potential.
